Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting

C J A Huibers; B T G M Sallevelt; J M J Op Heij; D O'Mahony; N Rodondi; O Dalleur; R J van Marum; A C G Egberts; I Wilting; W Knol

doi:10.1007/s41999-022-00633-5

Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting

C J A Huibers, B T G M Sallevelt, J M J Op Heij, D O'Mahony, N Rodondi, O Dalleur, R J van Marum, A C G Egberts, I Wilting, W Knol

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVE: To evaluate the agreement of hospital physicians and older patients with individualised STOPP/START-based medication optimisation recommendations from a pharmacotherapy team.

METHODS: This study was embedded within a large European, multicentre, cluster randomised controlled trial examining the effect of a structured medication review on drug-related hospital admissions in multimorbid (≥ 3 chronic conditions) older people (≥ 70 years) with polypharmacy (≥ 5 chronic medications), called OPERAM. Data from the Dutch intervention arm of this trial were used for this study. Medication review was performed jointly by a physician and pharmacist (i.e. pharmacotherapy team) supported by a Clinical Decision Support System with integrated STOPP/START criteria. Individualised STOPP/START-based medication optimisation recommendations were discussed with patients and attending hospital physicians.

RESULTS: 139 patients were included, mean (SD) age 78.3 (5.1) years, 47% male and median (IQR) number of medications at admission 11 (9-14). In total, 371 recommendations were discussed with patients and physicians, overall agreement was 61.6% for STOPP and 60.7% for START recommendations. Highest agreement was found for initiation of osteoporosis agents and discontinuation of proton pump inhibitors (both 74%). Factors associated with higher agreement in multivariate analysis were: female gender (+ 17.1% [3.7; 30.4]), ≥ 1 falls in the past year (+ 15.0% [1.5; 28.5]) and renal impairment i.e. eGFR 30-50 ml/min/1.73 m2; (+ 18.0% [2.0; 34.0]). The main reason for disagreement (40%) was patients' reluctance to discontinue or initiate medication.

CONCLUSION: Better patient and physician education regarding the benefit/risk balance of pharmacotherapy, in addition to more precise and up-to-date medical records to avoid irrelevant recommendations, will likely result in higher adherence with future pharmacotherapy optimisation recommendations.

CLINICAL TRIAL REGISTRATION: Trial Registration Number NCT02986425.

Original language	English
Pages (from-to)	541-552
Number of pages	12
Journal	European Geriatric Medicine
Volume	13
Issue number	3
DOIs	https://doi.org/10.1007/s41999-022-00633-5
Publication status	Published - Jun 2022

Bibliographical note

Funding Information:
European Union HORIZON 2020, Swiss State Secretariat for Education, Research and Innovation (SERI). This work is part of the project “OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly” supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No 6342388, and by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 15.0137. The opinions expressed and arguments employed herein are those of the authors and do not necessarily reflect the official views of the EC and the Swiss government. The funder of the study had no role in the study design; data collection, analysis and interpretation or writing of the report.

Publisher Copyright:
© 2022, The Author(s).

Keywords

Multimorbidity
Pharmacotherapy optimisation
Polypharmacy
STOPP/START criteria
Shared-decision-making CDSS

Access to Document

10.1007/s41999-022-00633-5Licence: CC BY

s41999-022-00633-5Final published version, 900 KBLicence: CC BY

Cite this

Huibers, C. J. A., Sallevelt, B. T. G. M., Heij, J. M. J. O., O'Mahony, D., Rodondi, N., Dalleur, O., van Marum, R. J., Egberts, A. C. G., Wilting, I., & Knol, W. (2022). Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting. European Geriatric Medicine, 13(3), 541-552. https://doi.org/10.1007/s41999-022-00633-5

@article{cb96a6cb88f5451db4cee76c5f5e704c,

title = "Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting",

abstract = "OBJECTIVE: To evaluate the agreement of hospital physicians and older patients with individualised STOPP/START-based medication optimisation recommendations from a pharmacotherapy team.METHODS: This study was embedded within a large European, multicentre, cluster randomised controlled trial examining the effect of a structured medication review on drug-related hospital admissions in multimorbid (≥ 3 chronic conditions) older people (≥ 70 years) with polypharmacy (≥ 5 chronic medications), called OPERAM. Data from the Dutch intervention arm of this trial were used for this study. Medication review was performed jointly by a physician and pharmacist (i.e. pharmacotherapy team) supported by a Clinical Decision Support System with integrated STOPP/START criteria. Individualised STOPP/START-based medication optimisation recommendations were discussed with patients and attending hospital physicians.RESULTS: 139 patients were included, mean (SD) age 78.3 (5.1) years, 47\% male and median (IQR) number of medications at admission 11 (9-14). In total, 371 recommendations were discussed with patients and physicians, overall agreement was 61.6\% for STOPP and 60.7\% for START recommendations. Highest agreement was found for initiation of osteoporosis agents and discontinuation of proton pump inhibitors (both 74\%). Factors associated with higher agreement in multivariate analysis were: female gender (+ 17.1\% [3.7; 30.4]), ≥ 1 falls in the past year (+ 15.0\% [1.5; 28.5]) and renal impairment i.e. eGFR 30-50 ml/min/1.73 m2; (+ 18.0\% [2.0; 34.0]). The main reason for disagreement (40\%) was patients' reluctance to discontinue or initiate medication.CONCLUSION: Better patient and physician education regarding the benefit/risk balance of pharmacotherapy, in addition to more precise and up-to-date medical records to avoid irrelevant recommendations, will likely result in higher adherence with future pharmacotherapy optimisation recommendations.CLINICAL TRIAL REGISTRATION: Trial Registration Number NCT02986425.",

keywords = "Multimorbidity, Pharmacotherapy optimisation, Polypharmacy, STOPP/START criteria, Shared-decision-making CDSS",

author = "Huibers, \{C J A\} and Sallevelt, \{B T G M\} and Heij, \{J M J Op\} and D O'Mahony and N Rodondi and O Dalleur and \{van Marum\}, \{R J\} and Egberts, \{A C G\} and I Wilting and W Knol",

note = "Funding Information: European Union HORIZON 2020, Swiss State Secretariat for Education, Research and Innovation (SERI). This work is part of the project “OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly” supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No 6342388, and by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 15.0137. The opinions expressed and arguments employed herein are those of the authors and do not necessarily reflect the official views of the EC and the Swiss government. The funder of the study had no role in the study design; data collection, analysis and interpretation or writing of the report. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jun,

doi = "10.1007/s41999-022-00633-5",

language = "English",

volume = "13",

pages = "541--552",

journal = "European Geriatric Medicine",

issn = "1878-7649",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

Huibers, CJA, Sallevelt, BTGM, Heij, JMJO, O'Mahony, D, Rodondi, N, Dalleur, O, van Marum, RJ, Egberts, ACG, Wilting, I & Knol, W 2022, 'Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting', European Geriatric Medicine, vol. 13, no. 3, pp. 541-552. https://doi.org/10.1007/s41999-022-00633-5

TY - JOUR

T1 - Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting

AU - Huibers, C J A

AU - Sallevelt, B T G M

AU - Heij, J M J Op

AU - O'Mahony, D

AU - Rodondi, N

AU - Dalleur, O

AU - van Marum, R J

AU - Egberts, A C G

AU - Wilting, I

AU - Knol, W

N1 - Funding Information: European Union HORIZON 2020, Swiss State Secretariat for Education, Research and Innovation (SERI). This work is part of the project “OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly” supported by the European Union's Horizon 2020 research and innovation programme under the grant agreement No 6342388, and by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 15.0137. The opinions expressed and arguments employed herein are those of the authors and do not necessarily reflect the official views of the EC and the Swiss government. The funder of the study had no role in the study design; data collection, analysis and interpretation or writing of the report. Publisher Copyright: © 2022, The Author(s).

PY - 2022/6

Y1 - 2022/6

N2 - OBJECTIVE: To evaluate the agreement of hospital physicians and older patients with individualised STOPP/START-based medication optimisation recommendations from a pharmacotherapy team.METHODS: This study was embedded within a large European, multicentre, cluster randomised controlled trial examining the effect of a structured medication review on drug-related hospital admissions in multimorbid (≥ 3 chronic conditions) older people (≥ 70 years) with polypharmacy (≥ 5 chronic medications), called OPERAM. Data from the Dutch intervention arm of this trial were used for this study. Medication review was performed jointly by a physician and pharmacist (i.e. pharmacotherapy team) supported by a Clinical Decision Support System with integrated STOPP/START criteria. Individualised STOPP/START-based medication optimisation recommendations were discussed with patients and attending hospital physicians.RESULTS: 139 patients were included, mean (SD) age 78.3 (5.1) years, 47% male and median (IQR) number of medications at admission 11 (9-14). In total, 371 recommendations were discussed with patients and physicians, overall agreement was 61.6% for STOPP and 60.7% for START recommendations. Highest agreement was found for initiation of osteoporosis agents and discontinuation of proton pump inhibitors (both 74%). Factors associated with higher agreement in multivariate analysis were: female gender (+ 17.1% [3.7; 30.4]), ≥ 1 falls in the past year (+ 15.0% [1.5; 28.5]) and renal impairment i.e. eGFR 30-50 ml/min/1.73 m2; (+ 18.0% [2.0; 34.0]). The main reason for disagreement (40%) was patients' reluctance to discontinue or initiate medication.CONCLUSION: Better patient and physician education regarding the benefit/risk balance of pharmacotherapy, in addition to more precise and up-to-date medical records to avoid irrelevant recommendations, will likely result in higher adherence with future pharmacotherapy optimisation recommendations.CLINICAL TRIAL REGISTRATION: Trial Registration Number NCT02986425.

AB - OBJECTIVE: To evaluate the agreement of hospital physicians and older patients with individualised STOPP/START-based medication optimisation recommendations from a pharmacotherapy team.METHODS: This study was embedded within a large European, multicentre, cluster randomised controlled trial examining the effect of a structured medication review on drug-related hospital admissions in multimorbid (≥ 3 chronic conditions) older people (≥ 70 years) with polypharmacy (≥ 5 chronic medications), called OPERAM. Data from the Dutch intervention arm of this trial were used for this study. Medication review was performed jointly by a physician and pharmacist (i.e. pharmacotherapy team) supported by a Clinical Decision Support System with integrated STOPP/START criteria. Individualised STOPP/START-based medication optimisation recommendations were discussed with patients and attending hospital physicians.RESULTS: 139 patients were included, mean (SD) age 78.3 (5.1) years, 47% male and median (IQR) number of medications at admission 11 (9-14). In total, 371 recommendations were discussed with patients and physicians, overall agreement was 61.6% for STOPP and 60.7% for START recommendations. Highest agreement was found for initiation of osteoporosis agents and discontinuation of proton pump inhibitors (both 74%). Factors associated with higher agreement in multivariate analysis were: female gender (+ 17.1% [3.7; 30.4]), ≥ 1 falls in the past year (+ 15.0% [1.5; 28.5]) and renal impairment i.e. eGFR 30-50 ml/min/1.73 m2; (+ 18.0% [2.0; 34.0]). The main reason for disagreement (40%) was patients' reluctance to discontinue or initiate medication.CONCLUSION: Better patient and physician education regarding the benefit/risk balance of pharmacotherapy, in addition to more precise and up-to-date medical records to avoid irrelevant recommendations, will likely result in higher adherence with future pharmacotherapy optimisation recommendations.CLINICAL TRIAL REGISTRATION: Trial Registration Number NCT02986425.

KW - Multimorbidity

KW - Pharmacotherapy optimisation

KW - Polypharmacy

KW - STOPP/START criteria

KW - Shared-decision-making CDSS

UR - https://www.scopus.com/pages/publications/85126271093

U2 - 10.1007/s41999-022-00633-5

DO - 10.1007/s41999-022-00633-5

M3 - Article

C2 - 35291025

SN - 1878-7649

VL - 13

SP - 541

EP - 552

JO - European Geriatric Medicine

JF - European Geriatric Medicine

IS - 3

ER -

Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this